Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dexmedetomidine for PSH Prevention in TBI
NCT04006054Phase 4Unknown
- Sponsor
- Xiangya Hospital, Central South University
- Start
- Jun 2019
- Primary completion
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of dexmedetomidine in Paroxysmal Sympathetic Hyperactivity (PSH) (2 arms), sponsored by Xiangya Hospital, Central South University. Primary endpoints: Epinephrine at 72 hours and Norepinephrine at 72 hours. Status: unknown.
02
Drugs
dexmedetomidine
03
Conditions
Paroxysmal Sympathetic Hyperactivity (PSH)
Beyond the preview
Go deeper on NCT04006054.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04006054.